Showing results (71-80 of 88) with videos related to
Sort By:
Pageof 9
Journal of Affective Disorders|February 11, 2021
Comments to Drs. Bahji, Vazquez, and ZarateWayne C Drevets, Vanina Popova, Ella J Daly, et al.Current Medical Research and Opinion|June 7, 2016
Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophreniaPhillip Pierce, Srihari Gopal, Adam Savitz, et al.Journal of Affective Disorders|June 30, 2017
Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trialAtul R Mahableshwarkar, Joseph R Calabrese, Thomas A Macek, et al.Pain|March 23, 2017
Sustained improvements in pain, mood, function and opioid use post interdisciplinary pain rehabilitation in patients weaned from high and low dose chronic opioid therapyKelly L Huffman, Taylor E Rush, Youran Fan, et al.Neuropsychiatric Disease and Treatment|September 2, 2017
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.Global Spine Journal|May 19, 2016
The Impact of Preoperative Depression and Health State on Quality-of-Life Outcomes after Anterior Cervical Diskectomy and FusionMatthew D Alvin, Jacob A Miller, Daniel Lubelski, et al.Brain : a Journal of Neurology|February 2, 2023
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind studyHana Florian, Deli Wang, Steven E Arnold, et al.Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 3, 2025
A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndromeAmee Revana, Rakesh Bhattacharjee, Jennifer L Miller, et al.Current Opinion in Pharmacology|February 26, 2014
New applications of disease genetics and pharmacogenetics to drug developmentAllen D Roses, Ann M Saunders, Michael W Lutz, et al.The Lancet. Neurology|February 20, 2021
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialGünter U Höglinger, Irene Litvan, Nuno Mendonca, et al.Pageof 9